uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach . Home Company About uniQure Management Supervisory Board Platform Gene Therapy Gene Therapy Approach Disease Areas Pipeline Clinical Pipeline Glybera Clinical Programs Preclinical Programs Partners Investors Shareholder Information SEC & Financial Reports Share Information Corporate Governance Media Latest Press Releases Events Scientific Publications search Latest News uniQure to Present at the Leerink Partners Rare Disease Roundtable Conference Sep 25, 2014 > Read More uniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs Sep 2, 2014 > Read More uniQure Acquires Cardiology Gene Therapy Company InoCard Aug 11, 2014 > Read More Chiesi and uniQure Provide Update on Glybera® Launch Aug 4, 2014 > Read More uniQure Secures Additional $10M Venture Loan from Hercules Capital Jul 1, 2014 > Read More Careers | Contact | Disclaimer | Press | RSS Feed